login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
AGIOS PHARMACEUTICALS INC (AGIO) Stock News
USA
- NASDAQ:AGIO -
US00847X1046
-
Common Stock
43.33
USD
+1.24 (+2.95%)
Last: 10/24/2025, 8:08:15 PM
43.3
USD
-0.03 (-0.07%)
After Hours:
10/24/2025, 8:08:15 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
AGIO Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
8 days ago - By: Agios Pharmaceuticals, Inc.
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
9 days ago - By: Agios Pharmaceuticals, Inc.
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
11 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
16 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
2 months ago - By: Zacks Investment Research
- Mentions:
VRTX
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?
21 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO
a month ago - By: Benzinga
- Mentions:
PBM
MTNB
HSDT
SSKN
...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
a month ago - By: Schall Law Firm
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm
3 months ago - By: Stocktwits
Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
3 months ago - By: Benzinga
- Mentions:
BSAC
BGC
RMNI
MTZ
...
Earnings Scheduled For July 31, 2025
2 months ago - By: Zacks Investment Research
- Mentions:
ADPT
ALLO
AKRO
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
2 months ago - By: Stocktwits
- Mentions:
VFMO
IWMW
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
2 months ago - By: Agios Pharmaceuticals, Inc.
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
2 months ago - By: Yahoo Finance
- Mentions:
BAC
Agios Pharmaceuticals, Inc. (AGIO) Advances Pipeline With Tebapivat, AG-236 in Rare Blood Disorders
3 months ago - By: Agios Pharmaceuticals, Inc.
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
3 months ago - By: The Motley Fool
Agios (AGIO) Q2 Revenue Jumps 45%
3 months ago - By: Agios Pharmaceuticals, Inc.
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: Agios Pharmaceuticals, Inc.
Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
Please enable JavaScript to continue using this application.